Compare CHE & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHE | FOLD |
|---|---|---|
| Founded | 1970 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.5B |
| IPO Year | 1994 | 2006 |
| Metric | CHE | FOLD |
|---|---|---|
| Price | $424.10 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $501.50 | $27.25 |
| AVG Volume (30 Days) | 239.1K | ★ 2.5M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 4.84 | N/A |
| Revenue | ★ $2,529,978,000.00 | N/A |
| Revenue This Year | $6.56 | $20.50 |
| Revenue Next Year | $6.23 | $18.59 |
| P/E Ratio | $88.08 | ★ N/A |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $365.21 | $5.66 |
| 52 Week High | $583.96 | $14.50 |
| Indicator | CHE | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 74.18 |
| Support Level | $420.28 | $14.21 |
| Resistance Level | $457.32 | N/A |
| Average True Range (ATR) | 12.71 | 0.02 |
| MACD | 2.66 | -0.00 |
| Stochastic Oscillator | 65.04 | 100.00 |
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.